Mayukh Sukhatme Sells 500,000 Shares of Roivant Sciences
Roivant Sciences' President & CIO, Mayukh Sukhatme, sold shares worth $17.07 million.
Key Points
- Mayukh Sukhatme, President & CIO of Roivant Sciences, sold 500,000 shares for $17.07 million on June 25, 2026.
- Roivant Sciences Ltd. trades on NasdaqGS with a market cap of approximately $24.51 billion and a 52-week high of $34.68.
- Analysts maintain a strong buy consensus for Roivant, with a target mean price of $39.04.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 25, 2026, Mayukh Sukhatme, the President and Chief Investment Officer of Roivant Sciences Ltd. (NasdaqGS: ROIV), sold 500,000 shares of the company. The transaction was valued at approximately $17.07 million, with an average price of $34.13 per share. This sale was not part of a pre-arranged trading plan.
Insider Buying and Selling at Roivant Sciences Ltd.
Mayukh Sukhatme, as President & CIO, made several transactions around this period. On June 26, 2026, he again sold 500,000 shares at an average price of $34.08. These sales follow a pattern of significant insider activity, although they were not planned trades.
Roivant Sciences Ltd. Stock Up 0.1%
Shares of Roivant Sciences Ltd. traded near $34.07 on Tuesday. The company, which operates in the biotechnology sector, boasts a market capitalization of about $24.51 billion. Although currently not profitable, Roivant holds a forward P/E ratio of -21.85. The stock's 52-week range is from $10.71 to $34.68, and it has a beta of 1.137, indicating moderate volatility. The company's liquidity appears strong with a current ratio of 18.37 and a quick ratio of 18.00.
$ROIV stock price
Daily closing prices, year to date. Not investment advice.
Analysts Set New Price Targets
Analysts remain bullish on Roivant Sciences. On May 26, 2026, Guggenheim maintained a buy rating with a price target of $36. Citigroup and TD Cowen also reaffirmed their buy ratings with targets of $42 and $41, respectively, on May 21, 2026. The consensus among analysts is a strong buy, with an average target price of $39.04 based on 12 opinions.
About Roivant Sciences
Roivant Sciences Ltd. is a clinical-stage biopharmaceutical company headquartered in London, United Kingdom. It focuses on developing and commercializing innovative medicines and technologies. The company is involved in several therapeutic areas, including autoimmune diseases and pulmonary hypertension. Roivant also offers advanced delivery platforms, such as lipid nanoparticle and ligand conjugate technologies. Founded in 2014, the company employs 721 people and is led by CEO Matthew Gline.
Bottom Line
The recent insider sale by Mayukh Sukhatme highlights significant activity within Roivant Sciences. Investors often track such moves for insights into company leadership's confidence. It's important to note that these transactions are disclosed after the fact and may not reflect ongoing sentiment. Roivant's stock remains a focus for analysts, with a strong buy consensus suggesting optimism about its future prospects.
Get Roivant Sciences Ltd. alerts
New 13F filings, insider trades, and analyst moves on $ROIV, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.